Vectiopep key facts
as of Oct 2026- Operator of a biotechnology company intended to develop cancer immunotherapies.
- Vectiopep is valued at approximately $3.0M as of Oct 2026 (last reported valuation).
- It has raised $460K; the latest was Early Stage VC in Jan 2025.
- Notable investors include Sofigama Investments, Dag Nurm, Ivo Remmelg, Missouri Innovation Center, Tartu TaeduPark — 6 tracked in total.
- Status: Privately Held (backing).
Vectiopep's last reported valuation, Apr 2024. Nothing priced has surfaced since.
- ·Watch Vectiopep: the Monday email on marks, rounds and moves
Vectiopep funding rounds
No funding rounds for Vectiopep are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Vectiopep valuation
Vectiopep's last reported valuation was $3 million in Apr 2024. No priced round, secondary trade or fund mark has surfaced since.
Vectiopep investors
6 investors are on record for Vectiopep, including Sofigama Investments, Dag Nurm, Ivo Remmelg and Missouri Innovation Center.
About Vectiopep
Operator of a biotechnology company intended to develop cancer immunotherapies. The company develops tissue-specific RNA delivery technologies using peptide-based carriers combined with mRNA therapeutics to target immune cells, enabling patients to activate their immune system to fight cancer.
- Sector
- Healthcare
- HQ
- Tartu, Estonia
- Founded
- 2022
- Employees
- 6
- Website
- vectiopep.ee/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.